ProMIS Neurosciences Announces Six-Month Interim Safety And Biomarker Results From Its PRECISE-AD Phase 1B Trial Of PMN310 In Patients With Mild Cognitive Impairment Due To Alzheimer’s; Early Biomarker Movement Consistent With Target Engagement
In the blinded interim analysis evaluating 136 AD patients, PMN310 was observed to have a favorable safety profile across all genotypes, with no cases of amyloid-related imaging abnormalities-edema (ARIA-E) reported as
A medicine company tested a new Alzheimer's drug on patients and found it was safe so far, with signs it's working the way they hoped. When companies show their medicine is safe early on, it's a good first step—but there's still lots of testing ahead before we know if it really helps people.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.